Highlights of the San Antonio Breast Cancer Symposium 2021

Professor Virginia Kaklamani speak about the novelties and state of the art treatment presented at SABCS 2021.

Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2, -3, and -7 studies

Professor Lisa A. Carey speaks about the MONALEESA-2, -3, and -7 trials of ribociclib + endocrine therapy in patients with HR+/HER2− advanced breast cancer.

Final results of KEYNOTE-355

Professor Javier Cortes speaks about the final results of KEYNOTE-355 trial, a Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.

PALLAS trial: Adjuvant palbociclib in HR+/HER2- early breast cancer

Professor Michael Gnant speaks about the final results from 5,760 patients in the randomized phase III PALLAS trial.

The DESTINY-Breast03 trial

Professor Sara Hurvitz speaks about trastuzumab deruxtecan vs. trastuzumab emtansine in patients with HER2+ metastatic breast cancer.